Table 3.
Comparison of clinical features between HRV‐positive and HRV‐negative inpatients with asthma exacerbations
| HRV N (%) | HRV single infection N (%) | |||||
|---|---|---|---|---|---|---|
| Variable | Single infection (n = 47) | Negative (n = 71) | P | HRV‐A (n = 16) | HRV‐C (n = 29) | P |
| Male:female | 23:24 | 47:24 | 0.062 | 5:11 | 16:13 | 0.124 |
| Age (median, month) | 40 | 43 | 0.658 | 48 | 37 | 0.109 |
| History of eczema | 13 (27.7) | 26 (36.6) | 0.311 | 4 (25.0) | 8 (27.6) | 1.000 |
| History of allergic conditions | 8 (17.0) | 18 (25.4) | 0.285 | 3 (18.8) | 5 (17.2) | 1.000 |
| Familial asthma | 28 (59.6) | 43 (60.6) | 0.858 | 10 (62.5) | 16 (55.2) | 0.634 |
| Cough | 47 (100) | 71 (100) | ‐ | 16 (100) | 29 (100) | ‐ |
| Rhinorrhea | 8 (17.0) | 12 (16.9) | 0.986 | 5 (31.3) | 3 (10.3) | 0.177 |
| Expectoration | 34 (72.3) | 47 (66.2) | 0.481 | 11 (68.8) | 21 (72.4) | 1.000 |
| Wheezing | 41 (87.2) | 58 (81.7) | 0.422 | 14 (87.5) | 26 (89.7) | 1.000 |
| Fever | 14 (29.8) | 39 (54.9) | 0.007 | 5 (31.3) | 9 (31.0) | 1.000 |
| Severe exacerbation | 16 (34.0) | 12 (16.9) | 0.032 | 5 (31.3) | 10 (34.5) | 0.826 |
| Length of hospitalization (median, day) | 5 (3‐8) | 5 (2‐16) | 0.388 | 5 (3‐6) | 5 (4‐8) | 0.250 |
| White blood cell (×109/L) | 12.38 ± 5.13 | 10.77 ± 4.87 | 0.041 | 12.16 ± 5.71 | 12.58 ± 5.05 | 0.868 |
| Neutrophils (%) | 64.70 ± 20.27 | 56.44 ± 21.95 | 0.043 | 64.50 ± 21.18 | 65.31 ± 19.85 | 0.915 |
| Lymphocyte (%) | 30.60 ± 18.50 | 39.03 ± 21.19 | 0.031 | 29.63 ± 18.42 | 30.62 ± 18.47 | 0.859 |
| CRP > 8 mg/L (%) | 6 (12.8) | 8 (11.3) | 0.805 | 3 (18.8) | 3 (10.3) | 0.737 |
| Platelet (×109/L) | 333 ± 102 | 321 ± 94 | 0.308 | 319 ± 106 | 337 ± 102 | 0.887 |
HRV indicates human rhinovirus. Categorical variables were compared using the chi‐squared test, and the continuous variables were compared using the Student's t‐test or the nonparametric Mann‐Whitney U‐test. Two‐sided P‐values of < 0.05were considered statistically significant.